Cleveland BioLabs Sees Large Decrease in Short Interest (CBLI)
Cleveland BioLabs (NASDAQ:CBLI) was the target of a large drop in short interest in the month of July. As of July 31st, there was short interest totalling 466,099 shares, a drop of 23.7% from the July 15th total of 610,774 shares, American Banking News reports. Approximately 0.9% of the shares of the stock are short sold. Based on an average daily trading volume, of 195,278 shares, the days-to-cover ratio is currently 2.4 days.
Cleveland BioLabs (NASDAQ:CBLI) opened at 0.42 on Friday. Cleveland BioLabs has a 1-year low of $0.33 and a 1-year high of $1.84. The stock’s 50-day moving average is $0. and its 200-day moving average is $0.59. The company’s market cap is $21.4 million.
Cleveland BioLabs (NASDAQ:CBLI) last issued its quarterly earnings data on Thursday, August 7th. The company reported ($0.09) earnings per share for the quarter.
Cleveland BioLabs, Inc (NASDAQ:CBLI), incorporated on June 5 2003, is a biotechnology company focused on developing biodefense, tissue protection and cancer treatment drugs based on the concept of modulation of cell death for therapeutic benefit.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.